← Back to home

Arqule, Inc., A Subsidiary Of Merck Sharp & Dohme Llc, A Subsidiary Of Merck & Co., Inc. (rahway, Nj Usa)

Clinical trials sponsored by Arqule, Inc., A Subsidiary Of Merck Sharp & Dohme Llc, A Subsidiary Of Merck & Co., Inc. (rahway, Nj Usa), explained in plain language.

Not yet finished but already full! 1

New pill shows promise for Tough-to-Treat blood cancers

Disease control Ongoing

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

Phase: PHASE1, PHASE2 • Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) • Aim: Disease control

Last updated May 13, 2026 16:01 UTC

Arqule, Inc., A Subsidiary Of Merck Sharp & Dohme Llc, A Subsidiary Of Merck & Co., Inc. (rahway, Nj Usa)

New pill shows promise for Tough-to-Treat blood cancers